We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site
The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without the manual effort and uncertainty of traditional methods. The area of each Optofluidic chip NanoPen™ chamber is ~700 times smaller than that of a microwell, leaving nowhere for “ghost cells” to hide.
Kim, L et al., Amgen. Read paper.
Download the application note on: FDA-Accepted Monoclonality Assurance on The Beacon® Optofluidic System for Cell Line Development to learn how the Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.